Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230]

Affiliations

• ¹ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States. Electronic address: cdezafra@amgen.com.
• ² Preclinical Safety, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
• ³ Nonclinical and Translational Sciences, Allergan, Irvine, CA, United States.
• ⁴ Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
• ⁵ Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
• ⁶ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States.